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Available online 13 June 2005We investigated whether cell proliferation and neurogenesis are altered
in R6/2 transgenic Huntington’s disease mice. Using bromodeoxyur-
idine (BrdU), we found a progressive decrease in the number of
proliferating cells in the dentate gyrus of R6/2 mice. This reduction was
detected in pre-symptomatic mice, and by 11.5 weeks, R6/2 mice had
66% fewer newly born cells in the hippocampus. The results were
confirmed by immunohistochemistry for the cell cycle markers Ki-67
and proliferating cell nuclear antigen (PCNA). We did not observe
changes in cell proliferation in the R6/2 subventricular zone, indicating
that the decrease in cell proliferation is specific for the hippocampus.
This decrease corresponded to a reduction in actual hippocampal
neurogenesis as assessed by double immunostaining for BrdU and the
neuronal marker neuronal nuclei (NeuN) and by immunohistochem-
istry for the neuroblast marker doublecortin. Reduced hippocampal
neurogenesis may be a novel neuropathological feature in R6/2 mice
that could be assessed when evaluating potential therapies.
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protein of yet unknown function (HDCRG, 1993). The disease is
invariably fatal and affected individuals show depression, a severe
motor impairment, dementia, and weight loss. The neuropathology
of the disease is characterized by accumulation of huntingtin in
neuronal intranuclear inclusions, as well as a progressive degen-
eration of neurons in the striatum, certain layers of the cerebral
cortex, and the hypothalamus (for review, Peterse´n and Brundin,
2002; Vonsattel and DiFiglia, 1998). The most used animal model
for studying the mechanisms underlying the pathogenesis of HD is
the R6/2 transgenic mouse model, which expresses exon 1 of
human mutant HD gene with approximately 150 CAG repeats
(Mangiarini et al., 1996). R6/2 mice display several features of the
human condition, including progressive motor (Carter et al., 1999)
and cognitive impairments (Lione et al., 1999; Murphy et al.,
2000), weight loss, decreased striatal and brain size (Mangiarini et
al., 1996), ubiquitinated nuclear and cytoplasmic inclusions of
mutant huntingtin (Davies et al., 1997), altered levels of neuro-
transmitters (Cha, 2000) and their receptors (Cha et al., 1998),
decreased expression of striatal signaling genes (Luthi-Carter et al.,
2000), and premature death (Mangiarini et al., 1996). Relatively
little neuronal death has been detected in the striatum and cerebral
cortex of R6/2 mice (Iannicola et al., 2000; Turmaine et al., 2000).
However, we recently described a progressive loss of orexin
neurons in the lateral hypothalamus of these transgenic HD mice
(Peterse´n et al., 2005). A loss of retinal ganglion neurons has also
been reported (Helmlinger et al., 2002).
Although initially thought to occur only during embryonic
development, recent studies have shown that neurogenesis occurs
throughout life and that there are significant numbers of neural
precursors in several regions of the adult mammalian brain. In fact,
proliferation and differentiation of new neurons are now known to
occur in selective regions of the adult brain, primarily in the
subventricular zone (SVZ) of the lateral ventricles and in the
subgranular zone (SGZ) of the dentate gyrus (DG) of the
hippocampus. Given this capacity of the adult brain to generate
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endogenous source of healthy cells for the treatment of certain
neurodegenerative diseases (for review, Lie et al., 2004; Mohapel
and Brundin, 2004). Also, it is not completely understood to what
extent the neurogenic process is altered in neurodegenerative
conditions since different groups have reported contradictory
results regarding alterations in neurogenesis in animal models
and patients of various disorders including Alzheimer’s disease
(AD) (Haughey et al., 2002a,b; Jin et al., 2004a,b) and Parkinson’s
disease (PD) (Fallon et al., 2000; Frielingsdorf et al., 2004;
Hoglinger et al., 2004; Zhao et al., 2003). In a recent report by
Curtis et al. (2003), an increase in cell proliferation and neuro-
genesis in the SVZ of HD patients was described. We have recently
found that cell proliferation is reduced in the DG of end-stage R6/2
mice (Gil et al., 2004). This is in agreement with a study by Lazic
et al. (2004), which showed a reduction in hippocampal cell
proliferation in R6/1 transgenic HD mice.
In the present study, we extend our previous observations, by
using several different markers to evaluate cell proliferation and
neurogenesis during the lifespan of R6/2 mice. Our results
demonstrate a dramatic decrease of cell proliferation in the DG
but not in the SVZ of these mice. This decrease can be detected
already at an early age. Furthermore, by using confocal micro-
scopy, we also showed that the reduction in hippocampal cell
proliferation corresponds to an actual decrease in the generation of
new neurons.Materials and methods
Transgenic mice
Transgenic HD mice of the R6/2 line were originally purchased
from Jackson Laboratories (Bar Harbor, ME, USA) and the colony
was maintained by breeding heterozygous R6/2 males with females
from their background strain (F1 of CBAC57Bl/6). Tails of the
offspring were used to obtain DNA for determination of the
genotype using a polymerase chain reaction assay (Mangiarini et
al., 1997). The mice were housed in groups with ad libitum access
to food and water at a 12-h light/dark cycle. All experimental
procedures conducted in this study were approved by the Ethical
Committee at Lund University.
Treatments and tissue processing
Generation of newborn cells was assessed by injecting 50 mg/
kg of the thymidine analogue bromodeoxyuridine (BrdU, in
phosphate buffer saline, PBS, pH 7.2; Sigma, Steinheim, Germany)
i.p. every 12 h for 3 consecutive days. At 3.5, 7.5, and 11.5 weeks
of age, mice were sacrificed 18 h after the last BrdU injection. To
analyze the neuronal differentiation of the newborn cells that
incorporated BrdU, a separate set of mice at the age of 5.5 and 10
weeks were sacrificed 2 weeks after the last BrdU injection, which
was administered at 3.5 and 8 weeks of age, respectively. Mice at 2
weeks of age were sacrificed without prior BrdU injection due to
their young age. Mice were deeply anesthetized with pentobarbital
and transcardially perfused with saline followed by paraformalde-
hyde (4%) in 0.1 M PBS. The brains were left in fixative overnight
and then dehydrated in 20% sucrose/0.1 M phosphate buffer. Six
series of coronal sections were cut throughout the brain on a sliding
microtome at a thickness of 30 Am.Immunohistochemistry
One series of free-floating sections was processed for BrdU
immunohistochemistry. Briefly, the sections were incubated in 1 M
HCl at 65-C for 30 min in order to denaturate the DNA. The
sections were then preincubated for 1 h in 5% normal horse serum
(NHS) and 0.25% Triton X-100 in PBS and then incubated for 48 h
at 4-C with a mouse monoclonal antibody against BrdU (1:50;
Dako, Glostrup, Denmark) in PBS containing 2% NHS. After
incubation with a biotinylated horse anti-mouse secondary anti-
body (1:200; Dakopatts, Copenhagen, Denmark) for 2 h, the bound
antibodies were visualized using an avidin–biotin–peroxidase
complex system (Vectastain ABC Elite Kit, Vector Laboratories,
Burlingame, CA, USA).
Separate series of sections were also processed for detection
of the proliferative marker Ki-67, the neural-specific intermediate
filament Nestin, and doublecortin, a marker for newly differ-
entiated and migrating neuroblasts. Briefly, after quenching in 3%
H2O2/10% methanol in 0.1 M PBS for 15 min, and preincubation
with the proper sera, the sections were incubated for 48 h at 4-C
with a mouse monoclonal antibody against Ki-67 (1:120,
Novocastra, Newcastle, UK), a monoclonal mouse anti-rat nestin
antibody (1:200, BD Biosciences Pharmingen, Heidelberg,
Germany), or a goat anti-doublecortin antibody (1:400, Santa
Cruz Biotechnology, Santa Cruz, CA, USA), respectively. The
sections were then incubated for 2 h with the respective
secondary antibodies (biotinylated horse anti-mouse, 1:200;
Dakopatts, and biotinylated horse anti-goat, 1:200; Vector
Laboratories), and visualized as described above.
Immunohistochemistry for the cell cycle marker proliferating
cell nuclear antigen (PCNA) was also performed. A separate
series of brain sections was first incubated in 10 mM sodium
citrate buffer (in PBS, pH 6.0) at 95-C for 5 min. This step was
repeated twice in order to unmask the antigens. After quenching
and preincubation with 5% normal swine serum (NSS) for 1 h,
the sections were incubated with a rabbit polyclonal antibody
against PCNA (1:200, Santa Cruz Biotechnology) for 48 h at
4-C. The sections were then incubated with a biotinylated swine
anti-rabbit secondary antibody (Dako), and visualized as
described above.
Neuronal differentiation was also assessed by BrdU/neuronal
nuclei (NeuN) double labeling. Briefly, after DNA denaturation
and preincubation in the proper sera, the sections were incubated
for 48 h at 4-C in monoclonal rat anti-BrdU (1:100, Immunolo-
gicalsDirect, Oxfordshire, UK) and mouse anti-NeuN (1:100,
Chemicon, Temecula, CA, USA) antibodies. The sections were
then incubated with the secondary antibodies Cy3-conjugated
donkey anti-rat IgG (1:200, Jackson ImmunoResearch, West
Grove, PA, USA) and biotinylated horse anti-mouse IgG (Vector
Laboratories) for 2 h, followed by incubation with Alexa-488-
conjugated streptavidin (1:200, Molecular Probes, Leiden, The
Netherlands) for 2 h.
Morphological quantification
All morphological analyses were performed on blind-coded
slides. The numbers of BrdU-, Ki-67-, PCNA-, nestin-, and
doublecortin-immunopositive cells in the SGZ of the DG of the
dorsal hippocampus were assessed by counting all positive cells
in 7 to 9 sections/mouse at the levels of bregma 1.34 to 2.80
using conventional light microscopy with a 40 objective. The
Fig. 1. Progressive reduction in the number of BrdU-labeled cells in the
dentate gyrus of R6/2 and wild-type mice. There was an age-related decline
in the number of BrdU-labeled cells in the DG of all mice (A). Compared to
wild-type littermates, R6/2 mice displayed significantly less BrdU-labeled
cells at all ages examined [two-factor ANOVA genotype F(1,38) = 46.97,
P < 0.0001; age F(2,38) = 80.93, P < 0.0001; age  genotype F(2,38) =
0.71, P = n.s.]. Representative sections of the DG processed for BrdU
immunohistochemistry in wild-type (B) and R6/2 mice (C) at 11.5 weeks of
age. Scale bar = 50 Am.
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cells assessed in 7–9 sections/mouse was expressed as the
average number of cells per section. Due to the large number of
positive cells in the SVZ, the total number of BrdU- and PCNA-
labeled cells in this region was estimated with stereological
techniques (Gundersen et al., 1998). We used a 100 objective
fitted on an Olympus BH2 microscope, an X–Y–Z step motor
stage run by an IBM PC computer, a CCD-IRIS color video
camera, and the CAST-GRID software (Olympus Denmark A/S,
Albertslund, Denmark). For systematic sampling, the frame area
(163 Am2) and the counting interval (x and y both 75 Am) were
set to allow for at least a total of 100 cells to be sampled in five
sections with the SVZ (ending at the level of bregma 0.14 with
the presence of the anterior commissure, and including four
anterior sections within one series) and the optical dissector was
set to sample all cells below the first 2.5 Am and above the last
2.5 Am of both surfaces of the section. The total volume of the
SVZ was assessed by multiplying the sum of the five areas
outlined above with the thickness of the sections (30 Am) and
the number of series (6), according to stereological principles
(Gundersen et al., 1998). For the sections that were processed
for BrdU/NeuN immunohistochemistry, 50 BrdU-labeled cells
per mouse were analyzed for co-labeling with NeuN, using a
confocal laser-scanning microscope (Leica DM IRE3 micro-
scope, Leica Confocal Software Version 2.77) at 1 Am optical
thickness.
Statistics
The data were analyzed with a two-factor analysis of variance
(ANOVA) or unpaired Student’s t tests, when appropriate, using
the Statview 5.4 package (Abacus Concepts, Berkeley, CA, USA).
Data are presented as mean T SEM. A P value of <0.05 was
considered statistically significant.Results
R6/2 mice exhibited decreased hippocampal cell proliferation with
increased disease progression
Using BrdU to label dividing cells, we observed an age-
related decline in the number of proliferating cells in mice of
both genotypes (Fig. 1). However, compared to wild-type
littermates, R6/2 mice exhibited significantly fewer BrdU-labeled
cells. Already at 3.5 weeks, R6/2 mice displayed a significant
21% reduction in the number of BrdU-positive cells compared to
wild-type littermates. A trend for a similar reduction (19%) in the
number of nestin-positive cells was detected at this age (wild-
type 377 T 25 cells/section, R6/2 304 T 24 cells/section,
Student’s t test P = 0.057). At 7.5 weeks, an age at which
motor symptoms are present, BrdU cell numbers further declined
to 43% compared to wild-type mice. At 11.5 weeks, at a more
advanced stage of motor symptoms, R6/2 mice showed a
reduction of 66% in BrdU-labeled cells compared to wild-type
mice (Fig. 1).
Ki-67 is a nuclear protein that is expressed in all phases of the
cell cycle except the resting phase and can be used as a marker
for proliferation in the initial phase of adult neurogenesis (Kee et
al., 2002). Therefore, we used this endogenous cell cycle marker
to assess cell proliferation in mice younger than 3.5 weeks. Wefound a non-significant trend towards a decrease in the number
of Ki-67-positive cells (20% reduction) in 2-week-old R6/2 mice
(Fig. 2A). Assessment of Ki-67-positive cells at 11.5 weeks of
age confirmed the BrdU analysis, with 72% fewer Ki-67-labeled
cells in R6/2 mice compared to wild-type littermates (Fig. 2).
Since the cell cycle marker PCNA has been used in a previous
study assessing cell proliferation in human HD tissue (Curtis et
al., 2003), we also used this marker to evaluate cell proliferation
in R6/2 mice. Again, we observed a non-significant trend
towards a decrease in the number of PCNA-labeled cells at the
early age of 2 weeks in R6/2 mice (10% reduction) (Fig. 3A).
However, this marker was less sensitive at detecting decreases in
cell proliferation at 11.5 weeks of age, since we only observed
about a 36% decrease in the number of PCNA-labeled cells
(Fig. 3), compared to 66% and 72% with BrdU and Ki-67,
respectively.
Decreased hippocampal neurogenesis both at early and at end
stage of disease in R6/2 mice
Three-and-a-half-week-old and 8-week-old mice were injected
with BrdU (every 12 h, during 3 days) and allowed to survive for
an additional 2 weeks before being sacrificed. The total number
of BrdU-labeled cells 2 weeks after the last BrdU injection was
significantly smaller in R6/2 compared to wild-type mice at both
timepoints (Fig. 4A). Interestingly, if the average number of
BrdU-labeled cells/section/genotype at 5.5 weeks (2 weeks post-
injection) was compared with the numbers at 3.5 weeks (18 h
Fig. 3. Reduced cell proliferation in the R6/2 dentate gyrus as assessed with
the cell cycle marker PCNA. There was a progressive decrease in the
number of PCNA-immunopositive cells with increasing age in the DG of
both R6/2 and wild-type mice (A). Significantly fewer PCNA-positive cells
were found in R6/2 mice [two-factor ANOVA genotype F(1,22) = 11.04,
P < 0.005; age F(1,22) = 840.09, P < 0.0001; age  genotype F(1,22) =
0.21, P = n.s.]. Representative sections of the DG processed for PCNA
immunohistochemistry in wild-type (B) and R6/2 mice (C) at 11.5 weeks of
age. Scale bar = 50 Am.
Fig. 2. Reduced cell proliferation in the R6/2 dentate gyrus as assessed with
the endogenous cell proliferation marker Ki-67. There was a progressive
reduction in Ki-67-positive cells in the DG of both R6/2 and wild-type mice
(A). The R6/2 mice displayed significantly fewer Ki-67-positive cells [two-
factor ANOVA genotype F(1,22) = 6.83, P < 0.05; age F(1,22) = 198.97,
P < 0.0001; age  genotype F(1,22) = 0.61, P = n.s.]. Representative
photomicrographs of the DG processed for Ki-67 immunohistochemistry in
wild-type (B) and R6/2 mice (C) at 11.5 weeks of age. Scale bar = 50 Am.
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type and 69% less BrdU-positive cells in R6/2 mice at 5.5 weeks
of age. Similarly, if the average number of BrdU-labeled cells/
section/genotype at 10 weeks (2 weeks post-injection) was
compared with the numbers at 7.5 weeks (18 h post-injection),
there were 73% less BrdU-positive cells in wild-type and 84%
less BrdU-positive cells in R6/2 mice at 10 weeks of age. The
procedure of waiting 2 weeks after the last BrdU injection
allowed us to determine the phenotype of the BrdU-positive cells.
By using confocal analysis, we estimated that about 80–90% of
the remaining BrdU-labeled cells co-expressed the specific
neuronal marker NeuN at both 5.5 and 10 weeks of age (Figs.
4B and C). In the 10-week-old mice, we observed a significant
65% decrease in the number of cells immunopositive for
doublecortin, a microtubule binding protein that is expressed in
newly differentiated and migrating neuroblasts (Brown et al.,
2003), further confirming the reduced neurogenesis in R6/2 mice
(Fig. 5).R6/2 mice exhibit normal proliferation in the subventricular zone
We began by evaluating the volume of the SVZ, another
neurogenic zone in the adult brain, in young and old R6/2 and
wild-type mice. The total volume of the SVZ was 0.072 T 0.004
mm3 in wild-type and 0.072 T 0.003 mm3 in R6/2 mice at 3.5
weeks, and 0.071 T 0.003 mm3 in wild-type and 0.057 T 0.003
mm3 in R6/2 mice at 11.5 weeks of age (two-factor ANOVA
revealed a significant difference between the age groups
[F(1,26) =5.28, P < 0.05], but no difference between the ge-
notypes [F(1,26) = 4.17, n.s.], nor any interaction between age and
genotype [F(1,26) = 4.08, n.s.]). We then examined the total
number of BrdU-labeled cells in this region and found no
significant differences between R6/2 and wild-type mice at either
3.5 or 11.5 weeks of age (Figs. 6A–C). Furthermore, the total
number of PCNA-positive cells in the SVZ did not differ between
R6/2 and wild-type mice at 11.5 weeks of age (Figs. 6D–F).
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Neurogenesis occurs continuously in two specific regions of the
adult brain, the SVZ and the SGZ of the DG in the hippocampus
(for review, see Lie et al., 2004). Although the functional impact of
adult neurogenesis in the hippocampus is not yet known
(Kempermann et al., 2004), it has been suggested to be involved
in important neuronal functions such as learning and memory (vanFig. 5. Decreased number of neuroblasts in the dentate gyrus of 10-week-
old R6/2 mice. The reduced hippocampal neurogenesis in R6/2 mice was
confirmed by a significant decrease in the number of doublecortin-
immunopositive neuroblasts in the DG of 10-week-old R6/2 mice as
compared to wild-type controls (Student’s t test, P < 0.01) (A).
Representative photomicrographs of the DG processed for doublecortin
immunohistochemistry in wild-type (B, C) and R6/2 mice (D, E) at 10
weeks of age. Scale bar = 50 Am (B, D), 20 Am (C, E).
Fig. 4. Decreased hippocampal neurogenesis in R6/2 mice. To study
whether the reduced cell proliferation reflected a decrease in neurogenesis,
5.5- and 10-week-old mice were sacrificed 2 weeks after the last BrdU
injection to allow for differentiation of the proliferating cells that
incorporated BrdU. A significant reduction in BrdU-labeled cells was
found in the DG of the R6/2 mice at both timepoints compared to wild-type
mice (A) [two-factor ANOVA genotype F(1,17) = 52.75, P < 0.0001; age
F(1,17) = 72.46, P < 0.0001; genotype  age F(1,17) = 12.99, P < 0.005].
In the DG of both 5.5- and 10-week-old wild-type and R6/2 mice, around
80–90% of the BrdU-labeled cells were NeuN-positive (B) [two-factor
ANOVA genotype F(1,17) = 3.50, P = n.s.; age F(1,17) = 9.85, P < 0.01;
age  genotype F(1,17) = 6.87, P < 0.05]. A representative confocal image
of a cell immunopositive for both BrdU (red) and NeuN (green) in the DG
of a 10-week-old R6/2 mouse (C). Scale bar = 8 Am.Praag et al., 2002). Recent studies indicate that damage to
surrounding brain regions can induce proliferation, migration,
and maturation of these neural precursors (Arvidsson et al., 2002;
Fallon et al., 2000; Parent et al., 2002). Impaired neurogenesis may
play a role in the pathogenesis of neurodegenerative disorders and
possibilities of restoring brain function by promoting neurogenesis
have emerged as potential therapeutic options (for reviews, see
Armstrong and Barker, 2001; Lie et al., 2004; Mohapel and
Brundin, 2004).
In this study, we report an age-related decline in hippocampal
cell proliferation, both in R6/2 mice and in wild-type littermates.
The progressive reduction in hippocampal cell proliferation in
wild-type mice is in agreement with a previous report showing
reduced cell proliferation in the rodent DG with aging (Bizon and
Gallagher, 2003). Importantly, R6/2 mice exhibited a more
dramatic reduction of proliferating BrdU-positive cells with age
than wild-type mice. Lazic and coworkers have recently shown a
decrease in hippocampal cell proliferation in R6/1 HD mice (Lazic
et al., 2004), and we previously reported a 70% reduction in BrdU-
labeled cells in the R6/2 hippocampus at 12 weeks of age (Gil et
al., 2004). In the present study, we extended the investigation by
establishing the progressive nature of the reduced cell proliferation
using different cell cycle markers such as BrdU, Ki-67, and PCNA.
Furthermore, we found that the reduced cell proliferation indeed
Fig. 6. No difference in cell proliferation in the subventricular zone between R6/2 mice and wild-type littermates. Cell proliferation in the SVZ of 3.5- and 11.5-
week-oldR6/2mice andwild-type littermateswas examined using stereological assessments of BrdU-labeled cells (A). The number of proliferating cells increased
with age [two-factor ANOVAF(1,26) = 4.98,P < 0.04] but no differenceswere found between the genotypes [ F(1,26) = 0.64,P = n.s.] norwas there an interaction
between age and genotype [ F(1,26) = 0.04, P = n.s.]. Representative sections of the SVZ processed for BrdU immunohistochemistry in wild-type (B) and R6/2
mice (C) at 11.5 weeks of age. Scale bar = 100 Am. The cell cycle marker PCNAwas also used to assess cell proliferation in the SVZ of 11.5-week-old R6/2 mice
(D). Again, no significant difference in the number of PCNA-positive cells was detected between the two genotypes (Student’s t test, P = n.s.). Representative
photomicrographs of the SVZ processed for PCNA immunohistochemistry in wild-type (E) and R6/2 mice (F) at 11.5 weeks of age. Scale bar = 100 Am.
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the surviving BrdU-labeled cells became neurons in both wild-type
and R6/2 mice, which is a similar percentage to what has been
reported previously (Duman et al., 2000). The study by Lazic et al.,
however, failed to detect any cells co-labeled for BrdU and NeuN in
R6/1 mice (Lazic et al., 2004). We found a reduction in BrdU-
labeled cells during the 2 weeks after the last injection. The massive
reduction in the number of BrdU-labeled cells commonly reported
after the first days up to more than 2 weeks post-injection is thought
to be due to cell death (Dayer et al., 2003; Gould et al., 1999).
Cell loss in the hippocampus of HD patients has been reported
in a few cases (Rosas et al., 2003; Vonsattel and DiFiglia, 1998).
However, no neuronal loss in the DG of the hippocampus occurs in
12-week-old R6/2 mice as assessed by stereology (Gil et al., 2004)
and Fluoro-Jade staining (Gil et al., unpublished observations).
Nonetheless, there is strong electrophysiological and behavioral
evidence for hippocampal dysfunction (Murphy et al., 2000).
Disturbed neurogenesis could be involved in this dysfunction.
Emerging evidence suggests that the expanded polyglutamine
in huntingtin can alter protein–protein interactions and thereby
interfere with vital cell functions (Li and Li, 2004). In a parallel
study, we detected a reduced number of BrdU-labeled cells in
pancreatic islets of 12-week-old R6/2 mice (Bjo¨rkqvist et al.,
2005). Evidence to link these two events arises from a recent studyshowing that normal huntingtin and the huntingtin-associated
proteins huntingtin-associated protein 1 and mixed-lineage kinase
2 modulate and stimulate the activity of the helix– loop–helix
transcription factor NeuroD (Marcora et al., 2003). NeuroD is
expressed in the pancreas, where it plays a crucial role in the
morphogenesis of normal islets (Huang et al., 2002), and in the
development of the DG (Liu et al., 2000). This relationship
between normal huntingtin, NeuroD, and genesis of new cells
raises the exciting possibility that an abnormal interaction between
mutant huntingtin and NeuroD could contribute, at least in part, to
the compromised generation of new cells observed both in the DG
and in the pancreas of R6/2 HD mice.
The underlying mechanism for the reduced neurogenesis in R6/
2 mice is however not known. Interestingly, brain-derived neuro-
trophic factor (BDNF), which stimulates cell proliferation in the
neurogenic zones (Benraiss et al., 2001; Pencea et al., 2001), is
down-regulated in HD (Canals et al., 2004; Luthi-Carter et al.,
2002; Spires et al., 2004; Zuccato et al., 2001). The dopaminergic
system, recently implicated in the regulation of neurogenesis
(Hoglinger et al., 2004), is also affected in HD. Experimental
depletion of dopamine in rodents decreased cell proliferation in the
DG and the SVZ and a selective agonist of D2-like receptors was
enough to completely restore proliferation (Hoglinger et al., 2004).
R6 mice display a deficient dopaminergic transmission (Bibb et al.,
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patients express reduced levels of tyrosine hydroxylase (Yohrling
et al., 2003) and a loss of D2 receptors (Cha et al., 1998; Weeks et
al., 1996). Whether reduction in BDNF levels or dysfunction in the
dopaminergic neurotransmission contributes to the observed
compromised neurogenesis in R6/2 mice remains to be evaluated.
In contrast to the decrease in cell proliferation/neurogenesis in
the R6/2 DG, we again observed no difference in the number of
proliferating cells in the SVZ between R6/2 and wild-type mice (Gil
et al., 2004). This is in contrast to findings in HD patients where
increased cell proliferation estimated by PCNA immunohistochem-
istry has been reported (Curtis et al., 2003). This discrepancy could
be due to factors such as a higher number of CAG repeats and
greater frequency of inclusions in R6/2 mice than in HD patients.
Moreover, it has been suggested that PCNA is expressed in cells
undergoing DNA repair (Tomasevic et al., 1998). Although BrdU
may be incorporated in any cell undergoing DNA synthesis, a
careful study by Cooper-Kuhn and Kuhn demonstrated that the
concentration in which BrdU is commonly used (50 mg/kg) is not
sufficient to detect cells undergoing DNA repair (Cooper-Kuhn and
Kuhn, 2002). Further analysis of HD brains using a combination of
several proliferative markers is therefore warranted.
In conclusion, hippocampal neurogenesis may be a new outcome
parameter to assess the efficacy of potential therapies in the R6/2 HD
transgenic mouse model, even though the underlying mechanism
causing a reduction is not yet known. Since neurogenesis may play a
role in hippocampal function, it is possible that therapies aimed to
restore hippocampal cell proliferation are beneficial.Acknowledgments
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